Antimicrobial Agents and Chemotherapy · 2008 · 52 citations · 13 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPharmacokinetic ModelingPopulation PharmacokineticsAntiretroviral TherapyMother-to-child Transmission PreventionNeonatal PharmacologyPediatric PharmacokineticsPerinatal PharmacologyPregnancy PharmacologyDrug Dosing In PregnancyEffect Compartment KineticsLiquid Chromatography-mass SpectrometryMaternal-infant PharmacokineticsPerinatal PharmacokineticsPharmacokinetics In NeonatesPharmacokinetics Of Antiretroviral DrugsPharmacotherapy In Pregnancy
The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets-two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h(-1) (61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters x h(-1), and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg x liter(-1) x h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg x liter(-1). We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.
13
Susan H. Eshleman, Donald R. Hoover, Shu Chen et al. · The Journal of Infectious Diseases · 2005 · 160 citations